CEBPZ and acute myeloid leukemia: When the two subtypes of CBF AML are considered, the majority of reports agree in conferring adverse prognosis in terms of relapse and sometimes [17,27] OS, mainly due to exon 17 mutation, in t(8:21) AML, as documented in some analyses restricted to D816 alteration, compared to other KIT mutations [14,26,32,41,46].